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Abstract
Background: MiRNA expression markers are well characterized in colorectal cancer (CRC), but less is known about
miRNA expression profiles in colorectal adenomas. Genome-wide miRNA and mRNA expression analyses were
conducted through the colorectal adenoma dysplasia sequence. Furthermore, analysis of the expression levels of
miRNAs in matched plasma samples was performed, focusing on biomarker candidates; miRNA and mRNA expression
analyses were performed on colorectal biopsies and plasma samples (20 normals; 11 tubular and 9 tubulovillous
adenomas; 20 colorectal carcinomas) by miRNA 3.0 and Human Transcriptome Array (Affymetrix) and validated by RT-
qPCR. Microarray data were analyzed using Expression Console and mRNA targets were predicted using miRWALK 2.0.
Results: Based on microarray analysis, 447 miRNAs were expressed in tissue and 320 in plasma. Twelve were upregulated
(miR-31, 8-fold p < 0.001) and 11 were downregulated (miR-10b 3-fold p < 0.001) in neoplastic lesions compared to
normal group. Eleven miRNAs showed altered expression between adenoma subtypes (miR-183 2.8-fold change,
p < 0.007). Expression level of 24 miRNAs differed between adenoma and CRC groups (including miR-196a, 3.5-fold).
Three miRNAs (miR-31, miR-4506, miR-452*) were differentially expressed in adenoma compared to normal both in tissue
and plasma samples. miRNA expression data were confirmed by RT-PCR both in plasma and matched tissue samples.
Conclusions: MiRNAs showed characteristic expression changes during CRC development in tissue. miRNAs were also
presented in plasma and positively correlated with matched tissue expression levels. The identified miRNA expression
changes could be verified RT-PCR methods facilitating routine application.
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Background
Colorectal cancer (CRC) is the third most common malig-
nant neoplasm worldwide [1]. Adenocarcinoma cells differ
from healthy epithelial cells having morphological, epigen-
etic, and genetic alterations, that are reflected in the altered
function of the epithelial cells in the colon. In the classic
model of tumorigenesis, CRC develops through polyps to
cancer, starting with an early development to adenoma
from an aberrant crypt foci followed by colorectal tumor
progression. This multistep process is influenced by several
underlying genetic and epigenetic alterations, as Fearon
and Vogelstein proposed [2].
Several studies have examined adenomas the intermedi-
ate step of colorectal carcinoma development [3, 4]. As
Kinzler and Vogelstein described, tubular adenomas can
transform into advanced adenomas with severe dysplasia
and a high risk of malignant progression finally evolving to
adenocarcinoma [5]. The adenoma-dysplasia-carcinoma
sequence has been genetically well evaluated and explored
by targeted and whole genome mutation analysis [6].
Analyses of multiple parallel gene expression alterations
are providing deeper insights into oncogenic transform-
ation. Several classes of screening targets have been devel-
oped in colorectal cancer: proteins [7], DNA [8], messenger
RNA [9], and microRNA (miRNA) [10]. Beside mRNAs,
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small RNA molecules are also involved in tumor progres-
sion: the miRNAs are 19–23 nucleotide long, non-coding
endogenous single-stranded RNAs that function as post-
transcriptional gene regulators by binding to their target
mRNAs [11]. miRNA expression alterations have been
observed in various types of human cancers including
breast cancer [12], hepatocellular carcinoma [13], colorectal
cancer [14], and lung cancer [15].
Deregulated microRNAs have an important role in pro-
gression of colorectal cancer but less is known about their
role in premalignant adenomas. Changes in the expression
pattern of miRNAs can be informative and highly signifi-
cant in the colorectal adenoma-carcinoma sequence pro-
gression as well. However, to date precancerous lesions
(such as adenomas) have been investigated less frequently
than cancers compared to healthy tissues [16, 17].
Possible miRNA-mRNA interactions can be predicted
using in silico prediction methods, that became [18] avail-
able using new (computer) algorithms and techniques
[19–21] which have made a more detailed analysis and
prediction possible [22] and improved knowledge about
cancer development.
During colorectal cancer development, release of nucleic
acids (DNA, mRNA, miRNA) can be observed in blood in
free circulating, protein, and exosome bound forms.
Circulating miRNAs can be detected in plasma, as well
[23]. Due to the stability of miRNAs, they can be used as
stable prescreening molecules in plasma samples, once
their sensitivity and specificity is proven. Microarray
technology allows characterization of tissue samples by
screening the expression level of thousands of genes simul-
taneously [24]. Recently, several studies have been pub-
lished using microarray platforms in addition, real-time
PCR array methods are already available to enable system-
atic, whole genome miRNA expression analysis in compari-
son between normal and tumor samples [4, 25, 26].
To date our research group has screened systematic
alterations of DNA methylation [27], mRNA expression
[28–30], and protein expression [31] in colorectal cancer
development. Furthermore, the Septin 9 plasma methy-
lation marker was also evaluated [32]. Analysis of
miRNAs, as part of an epigenetic regulatory network
complements our developing understanding of this com-
plex process.
The aim of the present study was to perform an additional
global miRNA microarray analysis of tubular and tubulovil-
lous adenoma biopsy specimen completed with colorectal
adenocarcinomas using fresh frozen and FFPE tissue.
Changes in miRNA expression patterns were also investi-
gated from plasma samples obtained from the same pa-
tients. Furthermore mRNA analysis was also performed
using Human Transcriptome Arrays 2.0, to allow integrated




The study protocol was approved by the local ethics com-
mittee (Semmelweis University Regional and Institutional
Committee of Science and Research Ethics; Nr.: ETT
TUKEB 23970/2011), and written informed consent was
provided by all patients. Patients did not receive chemo-
or radiotherapy prior to sample collection. Clinicopatho-
logical features can be found in Additional file 1: Table S1.
Fresh frozen colonic biopsy samples (approx. 3–5 mg
tissue specimens) from 20 colorectal cancer 20 normal
colorectal, 11 tubular and 9 tubulovillous adenoma tissues
were obtained during routine colonoscopy examinations.
Tissues were immediately placed in RNALater (Qiagen,
cat. no. 76104) and were stored at −80°C. FFPE specimens
were also collected and processed from parallel surgical
tissues. EDTA-stabilized peripheral blood samples were
obtained after approved consent (Table 1).
Isolation of total RNA including miRNA from fresh frozen
biopsies
Total RNA including miRNA was isolated from biopsy
samples using the High Pure miRNA Isolation Kit (Life
Science Roche, cat. no. 05080576001) according to the
manufacturer’s instruction, after homogenization with
MagNA Lyser instrument (Life Science Roche, cat. no.
03358976001). RNA integrity was evaluated using 2100
Table 1 Samples used in the study
Sample types Patients groups Methods
Normal Tubular adenoma Tubulovillous adenoma Adeno-carcinoma
FF tissue biopsy n = 20 n = 11 n = 9 n = 20 Microarray
Matched plasma n = 4 n = 4 n = 4 n = 4 Microarray
FF tissue biopsy (pooled) Pooled tissue samples Real-time PCR
n1 = 1–10
n2 = 11–20
n1 = 1–11 n1 = 1–9 n1 = 1–10
n2 = 11–20
Matched plasma n = 3 n = 3 n = 3 n = 3 Real-time PCR
FFPET surgical tissue n = 3 n = 3 n = 3 Real-time PCR
FF fresh frozen, FFPET formalin-fixed, paraffin-embedded tissue
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Bioanalyzer (Agilent, cat. no. G2940CA), and RNA yield
was quantified using Qubit 1.0 fluorometer (ThermoFisher
Scientific).
Total RNA isolation from FFPE specimen
Hematoxylin and eosin stained sections (10 μm) from
each formalin-fixed paraffin-embedded tissue blocks
were used for histological analysis.
Three tissue sections were cut from standard formalin-
fixed paraffin-embedded blocks and were transferred to a
microcentrifuge tube per isolation. Deparaffinization was
performed with 1 ml xylene for 10 min twice and washing
with 1 ml absolute ethanol for 10 min twice. miRNAs
were isolated from three air-dried deparaffinized sections
per isolation using the High Pure miRNA Isolation Kit.
miRNA isolation from plasma specimen
Peripheral blood samples were drawn into EDTA-
containing tubes and centrifuged at 1350 rpm for 12 min at
24 °C (room temperature). The supernatants were then cen-
trifuged with the same parameters in a second round. The
plasma samples were stored at −20 °C until use. The
miRNA fraction was extracted using the QIAamp Circulat-
ing Nucleic Acid Kit (Qiagen, cat. no 55114) with the fol-
lowing protocol: 1 ml of plasma was mixed with 100 μl
proteinase K (Qiagen, cat. no. 55114) and 800 μl ACL buffer
(Qiagen, cat. no. 55114), and samples were incubated at 60 °
C for 30 min. Then 1800 μl ACB Buffer (Qiagen, cat. no.
55114) and 3 ml isopropanol were added to the mix, and
the tubes was gently inverted a few times. Tubes were then
incubated at −20°C overnight. The mixture was filtered
through the column followed by washing steps with 1 ml
70% and 1 ml absolute ethanol. RNA was eluted in 30 μl
puffer AVE (Qiagen, cat. no.55114).
Tissue and plasma miRNA microarray and mRNA
expression profiling by Human Transcriptome Array 2.0
The miRNA expression profiles were analyzed by Gene-
Chip miRNA 3.0 array (Affymetrix, cat. no.902413). 1 μg
of total RNA including miRNA from tissue, and the total
amount of eluted miRNA fraction from plasma samples
were biotin-labeled using the Flashtag Biotin HSR RNA
Labeling Kit (Affymetrix, cat. no.901911). The samples
were hybridized for 16 h in a GeneChip Hybridization
Oven 645 (Affymetrix, cat. no. 00-0331), then were
washed and stained using a GeneChip Fluidics Station 450
(Affymetrix, cat. no. 00-0079) with the FS450_0002 fluid-
ics protocol and scanned with a GeneChip® Scanner 3000
7G (Affymetrix, cat. no.00-0210).
Out of the 60 fresh frozen biopsy tissue samples, 20 (7
normal, 2 tubular, 4 tubulovillous adenoma, and 7 tumor)
were selected for mRNA expression analysis using a Gene-
Chip Human Transcriptome Array 2.0 (Affymetrix, cat.
no.902162) according to the manufacturer’s instructions.
Real-time quantitative PCR array analysis from fresh
frozen and individual FFPE tissue specimen
40 ng of total RNA including miRNA was reverse tran-
scribed using the miRCURY LNA™ Universal RT cDNA
Synthesis Kit (Exiqon cat. no. 203301). The cDNA template
was then amplified using the microRNA Ready-to-Use
PCR, Human Panel I + II (Exiqon) in 384-well plates
according to the manufacturer’s instruction. The qPCR re-
actions were run on a LightCycler 480 System (Life Science
Roche) using the thermal-cycling parameters recommended
by Exiqon (Denaturation at 95 °C 10 min, 45 amplification
cycles at 95 °C 10 s 60 °C 1 min). The amplification curves
were analyzed by LightCycler 480 Software (Life Science
Roche, cat. no. 04994884001). From the 768 wells, 742
miRNA primer sets were used for miRNA expression profil-
ing, there remaining wells contained interplate calibrator
oligonucleotides, spike-in control oligonucleotides, and
empty wells. Hsa-miR-423-5p was used for normalization.
The relative quantification of miRNA expression levels was
performed using delta deltaCp method [33].
In silico miRNA-mRNA target prediction
Three miRNA were selected: miR-31 has the highest fold
change in normal vs. adenoma normal vs. CRC comparison;
miR-4417 and miR-497 were one of the continuously up-
regulated or downregulated miRNAs in adenoma-
carcinoma transition and their mRNA targets were pre-
dicted using five algorithm: TargetScan, miRanda, PIC-
TAR2, RNAHybrid and miRWalk on miRWalk 2.0
platform. Using DAVID tools (The Database for Annota-
tion, Visualization and Integrated Discovery v6.7) we ac-
quired pathway enrichment from gene ontology. Through
the KEGG pathway databases, we examined the pathway
target enrichment (p < 0.01) of selected groups of miRNAs
according to Yin et al. [34].
Immunohistochemistry
Immunohistochemistry for Cyclin D1 was performed on
formalin-fixed and paraffin-embedded tissue samples from
normal (n = 15) adenoma (n= 15) and CRC (n = 10) patients
(all samples diagnosed in H&E serial sections by an expert
pathologist). Following deparaffinization and rehydration,
microwave-based antigen retrieval was performed in TRIS
EDTA buffer (pH 9.0) (900 W/10 min, then 340 W/40 min).
Samples were immunostained with Cyclin D1 monoclonal
antibody (clone SP4: Histopathology Ltd., Hungary, cat no.
10074, 1:100 dilution) and diaminobenzidine-hydrogen
peroxidase–chromogen substrate system (HISTOLS-DAB,
Histopathology Ltd., cat. no. 30014.K) were used. Slides were
digitalized by Pannoramic 250 Flash II scanner (3DHIS-
TECH Ltd.), and digital slides were semi-quantitatively
analyzed with Pannoramic Viewer (ver.:1.15.3; 3DHIS-
TECH) based on Q score method (scored by multiplying
the percentage of positive cells (P) by the intensity (I: +3, +2,
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+1, 0). Formula: Q = P × I; maximum= 300). Primarily we
examined separately the epithelial and stromal compart-
ments, then summarize (Σ) these scores (ΣQ score max-
imum: 600) in order to remain comparable with our
miRNA and mRNA expression analyses using whole biopsy
samples.
Statistical analysis
Probe cell intensity files of microarrays were analyzed
using Expression Console Software (Affymetrix). The
robust multichip averaging (RMA) algorithm was used for
background correction normalization and probe level
summarization. GeneChip miRNA 3.0 array contains probe
sets for 1733 mature miRNAs. Human Transcriptome
Array 2.0 files were analyzed using Expression Console
Software and Transcriptome Analysis Console (Affymetrix).
Values of p < 0.05 were considered as statistically significant
with a logFC > |1|.
Results
Identification of expressed miRNAs in diagnostic groups
The absolute numbers of expressed miRNAs in the ana-
lyzed sample groups were determined based on the intensity
values of oligonucleotide probes for 1733 human mature
miRNAs that are synthesized on the surface of GeneChip
miRNA 3.0 arrays. Present values (based on hybridization)
were calculated by Expression Console Software (Affyme-
trix) using the statistical present/absent calls method.
From the 1733 mature miRNA probe sets, 442 had
positive values in normal tissue samples, 460 present
values were detected in adenoma (tubular and tubulovil-
lous) tissue samples, and 441 present values were de-
tected in colorectal carcinoma tissue samples (Fig. 1).
There were no significant differences in detection calls
between the diagnostic groups. The present/absent calls
in matched plasma samples from the same diagnostic
groups were also observed, 306 miRNAs were observed
in the plasma of normal subjects, 334 miRNAs in the
plasma of adenoma patients, and 321 miRNAs in the
plasma of patients with colorectal cancer (Fig. 1).
miRNA expression in different patient groups
Microarray analysis
miRNA microarray analysis was performed on biopsy
tissue samples from healthy patients and also from pa-
tients with tubular or tubulovillous adenoma or colorectal
cancer. Along the colorectal adenoma-carcinoma transi-
tion, based on our microarray profiling 19 continuously
upregulated or downregulated miRNAs were selected
(Fig. 2). Expression elevation could be observed in case of
miR-4417 which was upregulated 2.8-fold in adenoma
compared to normal samples, moreover, this expression
level was further elevated (1.9-fold) in CRC samples. Inter-
estingly, miRNA-378 family (-i;-f;-e;-g;-*) members are
represented highly in downregulated groups of miRNAs.
Eight (without miR-378 variants) downregulated miRNAs
showed approx. 1.4-2.4-fold lower expression in adenomas
compared to healthy, and reduction was 1.5-3-fold lower
in carcinoma samples (Fig. 2).
Figure 3a represents a heatmap of microarray data de-
scribing the miRNA expression profiles in precancerous
and neoplastic lesions vs. normal samples. Twenty-three
miRNAs (11 downregulated and 12 upregulated) were sig-
nificantly differentially expressed in healthy normal colonic
tissue vs. precancerous and neoplastic lesions. The expres-
sion of all 12 upregulated miRNAs were increased at least
2-fold in tissues from the normal-adenoma-carcinoma se-
quence progression. The highest miRNA expression alter-
ation was observed in case of miR-31 showing eightfold
higher expression both in adenoma and in CRC tissue com-
pared to normal samples (Additional file 2: Table S2).
Fig. 1 Number of miRNAs (considered as present) expressed in tissue and plasma samples. N normal; ADtub tubular adenoma; ADtubvill
tubulovillous adenoma; CRC colorectal cancer
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24 miRNAs showed characteristic differences between
adenoma and colorectal cancer samples. Only five miR-
NAs were upregulated in colorectal cancer compared to
adenoma (Fig. 3b).
When we selected miRNAs to characterize tubular vs.
tubulovillous adenoma, 11 miRNAs showed altered
expression between the adenoma subgroups. miR-489
expression showed the greatest difference between
adenoma subtypes with a > 4.5-fold increase in tubulo-
villous adenoma samples. The fold change of other miR-
NAs with significantly altered expression were in the
range of 2–4 (Fig. 3c).
By the analysis of microarray data, 12 differentially
expressed miRNAs could be detected between different
stages of colorectal cancer (Fig. 3d). The majority of miR-
NAs showed overexpression in Dukes D stage samples.
Interestingly, members of miR-378 family were highly
represented in this comparison, as well as in the groups
with continuously changing expression in adenoma to
carcinoma progression.
Interestingly, most of the differentially expressed miRNAs
in the adenoma-CRC comparison were upregulated in ad-
enomas compared to CRC samples (Fig. 3b). Therefore, we
focused on these adenoma-specific miRNA groups and se-
lected those ones which are upregulated in adenomas but
after significantly downregulated in CRC patients. Figure 4
represents four miRNAs showing the highest overexpres-
sion in adenoma samples. Levels of miR-182, miR-183*,
miR-96, and miR-34a are decreased 1.5-fold or higher in
carcinoma tissue samples compared to adenoma.
miRNA microarray validation
In order to confirm the accuracy and reliability of the
microarray data, the same tissue/RNA samples as used in
miRNA microarray analysis were analyzed using the miR-
CURY Human Panel real-time PCR (Exiqon) containing
742 mature miRNA oligonucleotides. RT-PCR validation
was done on four tissue samples pooled (with equal ng of
RNA of the samples in each group) according to the
Fig. 2 Bar charts showing the continually upregulated and downregulated miRNAs during cancer progression based on microarray data in tissue
samples. Green color represents healthy tissues, yellows are adenomas, red colors are colorectal cancer samples (p < 0.05, logFC > |0.5)|
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analyzed diagnostic groups (normal, CRC, tubular aden-
oma, and tubulovillous adenoma).
miRNAs showing altered expression in precancerous and
cancerous lesions by microarrays were selected, and the
expression tendencies were detected by real-time PCR
validation (Fig. 3e). The results of the analysis confirmed
the majority of our microarray data, except for six miRNAs:
miRNA-4417 was not represented in the PCR panels,
miRNA-183* assay did not give any signal, and four miRNA
assays including miR-299-5p, miR-20b, miR-195, and miR-
215 had outlier signals in pooled PCR patient groups.
miRNA target prediction and validation on Human
Transcriptome Arrays
Based on the Human Transcriptome Array 2.0 mRNA
expression results, downregulated mRNA targets were
selected. Three miRNAs were selected: miR-31 has the
highest fold change in normal vs. adenoma, normal vs.
CRC comparison; miR-4417 and miR-497 were one of the
continually upregulated or downregulated miRNAs in
adenoma-carcinoma transition. mRNA targets were pre-
dicted on miRWalk 2.0 platform in silico. Parallel analysis
on Human Transcriptome Arrays representing > 245,000
coding transcripts was performed. The selected mRNA
targets of the miRNAs can be seen on Fig. 5. The mRNA
expression pattern was observed inverse compared to the
miRNA expression pattern.
Deregulated miRNAs’ biological function and pathway
analysis by KEGG and GO database
Target genes of the continuously overexpressed and
underexpressed miRNAs during CRC development
Fig. 3 a Heatmap showing differential miRNA expression in diseased vs normal control group. Green color indicates lower than mean intensity,
and red represents higher than mean intensity. Each row represents a miRNA and each column represents a sample (p < 0.05, logFC > |1)|. b
Comparison of tubular and tubulovillous adenoma with colorectal cancer tissue samples. Each row represents a miRNA. Each column represents a
tissue sample. Selected miRNAs are sorted by statistical conditions: p< 0.05, logFC > |1|. c Comparison of tubular and tubulovillous adenoma
samples. Each row represents a miRNA. Each column represents a tissue sample. Selected miRNAs are sorted by statistical conditions: p< 0.05,
logFC > |1|. d Cluster analysis of Dukes B and D stages. Results based on three miRNAs showed significant expression alteration between groups
(p < 0.05). e Real-time PCR (E/2) validation of microarray (E/1) results in fresh frozen biopsy tissue samples. N normal; AD tubular adenoma; ADTV
tubulovillous adenoma; CRC colorectal cancer
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(without miR-378 homologues) (Fig. 2) participate in path-
ways related to signal transduction (PI3K-Akt KEGG path-
way ID: hsa04151, MAPK-KEGG pathway ID: hsa04010)
and cancer (KEGG pathway ID:hsa05200) from the top 24
selected KEGG pathways. GO analysis was also conducted
on these miRNAs revealing transcription regulations and
cell proliferations. (Additional file 3: Tables S3 and S4).
Target genes of four miRNAs showing the highest expres-
sion in adenomas (Fig. 4) could be related to the following
pathways: microRNAs in cancer (ID: hsa05206), pathways
in cancer (ID: hsa05200) (Additional file 3: Tables S7 and
S8). These predicted genes are involved mostly in DNA
transcription regulation and cell proliferations.
Analysis of fresh frozen tissue samples and FFPE surgical
samples by real-time PCR
Delta Cp values of pooled fresh frozen tissue samples
and FFPE tissue samples were visualized on graphs
(Fig. 6). The expression of most miRNAs slightly corre-
lated in fresh frozen and FFPE tissue types. These miR-
NAs could be abundant and are less affected by tissue
processing (miR-135b, miR-196b, miR-31). There were
some miRNAs whose expressions were more influenced
by the sample processing types (FF or FFPE). Expectedly,
miRNAs can be isolated more efficiently from fresh fro-
zen samples than from paraffin embedded tissues, how-
ever, about more than 60% (N-67%, A-65%, CRC-71%)
of miRNAs expressed in FFPE tissues. Interestingly,
among the 742 miRNAs represented on the Exiqon Hu-
man Panel I + II PCR plates, 50% (N-44%, A-44%, CRC-
48%) could be detected only in fresh frozen samples but
not in FFPE tissues.
Microarray results of matched plasma samples
To investigate the clinical potential of miRNAs detected
in tissue, plasma samples were collected from the same
patients and miRNA microarray analysis was performed.
Four miRNAs were found to be expressed in both tissue
and plasma samples moreover, in each sample type the
selected miRNAs showed the same expression tendency
with miRNAs showing altered expression between diag-
nostic groups (visualized by boxplots) (Fig. 7).
Fig. 4 miRNAs showing the highest overexpression in adenomas (but then downregulated in carcinoma). N normal; AD tubular adenoma; ADTV
tubulovillous adenoma; CRC colorectal cancer
Nagy et al. Clinical Epigenetics  (2017) 9:22 Page 7 of 14
Immunohistochemistry of Cyclin D1
The normal epithelium showed low nuclear Cyclin D1
expression (representative scoring values: 0; +1; Q
score: 26.66 ± 8.16), whereas among all stromal cells
only few showed strong immunoreaction, (+2 and +3)
(Q score: 12.67 ± 3.19 and ΣQ score: 39.32 ± 8.63;
Fig. 8a). The stromal protein expression was low, but
significantly (p < 0.05) increased in adenomas (Q score:
17.50 ± 5.77) and in CRCs (Q score: 19.00 ± 7.34). Het-
erogenic, significantly (p < 0.05) increased nuclear Cyc-
lin D1 expression (representative scoring values: +2;
+3) was detected in epithelial compartment of aden-
omas (Q score: 80.00 ± 17.88; Fig. 8b) and CRCs (Q
score: 129.50 ± 45.85; Fig. 8c). The detailed Q scores of
examined sample groups are illustrated on (Fig. 8d).
The detected total protein level alteration along the
adenoma-carcinoma transition of the analyzed colorectal
tissue samples was fundamentally constituted by the
increased epithelial cyclin D1 expression (adenoma ΣQ
score: 96.25 ± 18.75 and CRC ΣQ score: 147.00 ± 48.94.
(N vs. Ad and Ad vs. CRC: p < 0.05)).
Discussion
In this study, we have carried out a high throughput screen-
ing of microRNA expression alterations by microarray
analysis in tubular, tubulovillous colorectal adenoma, and
adenocarcinoma samples. Healthy colonic tissue samples
and parallel plasma samples were also evaluated from the
same patients. The numbers of expressed miRNAs between
the different patients groups are nearly balanced, although
less miRNAs were expressed in plasma samples compared
with matched tissue samples (approximately 300–330 miR-
NAs/samples group). Slattery et al. also found less than 600
expressed miRNAs in colonic tissues on a different micro-
array platform (Agilent) [3]. Leidinger et al. found that aver-
age number of detected miRNAs in control plasma samples
was 331, and the overall number of detected miRNAs in
plasma of lung cancer patients was between 264 and 364
from a set of 1205 miRNAs analyzed [35].
Genome-wide miRNA expression-profiling studies using
high throughput technologies frequently apply compari-
sons of normal-adenoma or normal-carcinoma pairs
(Additional file 1: Table S1). Here, we have performed a
Fig. 5 Selected miRNAs with continuous expression alteration along the colorectal adenoma-carcinoma sequence. Left box plots represent the
miRNA expression in tissues. Heatmaps represent the target mRNA expression in tissues. N normal; A adenoma; CRC colorectal cancer. (see full
names of genes are in list of Abbrevations)
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comparison of control normal vs. precancerous and neo-
plastic lesions (adenomas and tumor samples). We have
focused on those short RNAs which are continuously up-
regulated or downregulated through adenoma-carcinoma
progression. The continuous downregulation observed in
adenoma-carcinoma samples in case of miR-375, miR-
378, miR-139-5p, miR-133a, and miR-422a was confirmed
by others [36–44]. MiR-378 could inhibit tumor growth
and invasion partly by targeting vimentin in colorectal
cancer [39]. Functional analysis of miR-133a revealed that
it can inhibit CRC cell growth and metastasis by targeting
LIM and SH3 protein. It represses the MAPK pathway as
well, as shown after predicted KEGG pathway analysis
[43]. Lower expression of miR-422a was associated with
advanced stages of colorectal cancer thus proving its
tumor suppressive role [44].
MiR-503 and five other miRNAs (miR-4417, miR-18a,
miR-431, miR-1246, and miR-18b) were the only short
RNAs, which showed significant upregulation
through the normal to adenoma (dysplasia) transition in
our analysis. Selected miRNAs have a role in tumor pro-
gression, as e.g., miR-503 directly targets L1 adhesion
molecule (L1CAM) [45] and E2F transcription factor 3
(E2F3) [46] mRNAs involved in tumor progression. Out
of the four adenoma-specific miRNAs (miR-34a, miR-96,
miR-182, miR-183*) miR-96, miR-182 expression
changes were proven in adenoma and carcinoma sam-
ples by Wang et al. in a deep sequencing study with a
real-time PCR validation [47]. Furthermore, miR-182 has
been reported to suppress ENTPD5 expression which
is involved in energy metabolism. Previously, a decreased
expression of ENTPD5 mRNA and protein levels was
observed during adenoma carcinoma transition [48, 49].
In our study, strong emphasis was placed on explor-
ation of altered miRNA expression patterns in the early
benign lesions including the comparison of different
adenoma subtypes. Among others, we observed > two-
fold decreased expression of miR-3175, miR-720, miR-
4508 and miR-4492 in tubulovillous adenoma compared
to tubular adenoma samples. Of interest, miR-3175 ex-
pression was also reported to be reduced in gastric
adenocarcinoma cell line [50]. Interestingly, elevated
miR-720 levels were found in both adenoma subtypes
compared to healthy tissue samples. However, expres-
sion levels also differed significantly between adenoma
subgroups. Nevertheless, an early increasing expression
of miR-720 was observed through normal to adenoma
transformation, its concentration was more than 2-fold
lower in tubulovillous compared to tubular adenoma tis-
sues. Schopman et al. reported that miR-720 is not a
classic miRNA, but rather a fragment of a tRNA [51]. It
is also known as a novel serum biomarker of CRC [52].
Fig. 6 Correlation between miRNA expression in formalin-fixed, paraffin-embedded (FFPE), and fresh frozen (FF) colonic tissue. dCP values were
illustrated in graphs. Axis of X contains all the detected raw Cp values of each miRNA in case of FFPE tissues, axis of Y contains all the detected
raw Cp values in case of fresh frozen tissue samples
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Interestingly, miR-489 was found to be the most overex-
pressed miRNA between adenoma subtypes though its
downregulation was observed in CRC and was also asso-
ciated with other tumor types (Additional file 1: Table
S1) [53, 54]. From the 24 miRNAs which could differ-
entiate between adenoma-carcinoma, the overex-
pressed miR-223 was a validated oncomiR in CRC
invasion and metastasis [55].
In this study, we also demonstrated that miRNA de-
tection efficiency differed in distinct sample types
such as fresh frozen and FFPE samples. Interestingly,
more miRNA signals could be observed in FFPE than
in fresh frozen tissues. Differences in the optimization
of isolation protocols or application of pooled samples
in case of fresh frozen tissues could cause this
phenomenon.
Fig. 7 miRNA expression shows the same tendency in tissue and plasma samples. N normal; AD tubular adenoma; ADTV tubulovillous adenoma;
CRC colorectal cancer
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We also analyzed the appearance of tissue miRNA ex-
pression changes in peripheral blood. In case of several
miRNAs, a positive correlation was found between their
expression in tissue and plasma samples. miR-187 was
downregulated in colorectal cancer compared to nor-
mal controls, and its decreased expression tendency
could also be detected in the plasma of CRC patients
compared with healthy control patients. In a similar way,
downregulation of miR-187 has been shown in renal cell
carcinoma both in tissue and in plasma samples [56].
In silico target prediction of selected miRNAs, such as
miR-31 and miR-4417 which are upregulated in tumor
samples [57, 58], revealed a set of potential target mRNAs
including Flavin containing monooxigenase 4 (FMO4),
cyclin dependent kinase inhibitor 2B (CDKN2B), and pros-
taglandin D2 receptor (PTGDR), whose expression pattern
changed oppositely according to our (Human Transcrip-
tome Array 2.0 microarray) results. FMO4 is influenced by
miR-31. FMO4 catalyzes NADPH-dependent oxidative me-
tabolism and is downregulated in carcinoma cells by miR-
31 [59]. Among the targets of miR-4417, PTGDR is down-
regulated in CRC which can be caused by promoter hyper-
methylation, as well [60].
“Previous studies reported that the highly conserved
miR-195/497 cluster was significantly downregulated in
gastric, breast, bladder, liver, and also in colorectal can-
cer [61–66]. Although, our investigation was limited to
determine the expression level of miR-497 and its
predicted target, CCND1 mRNA and protein level ac-
cording to several functional analyses - such as luciferase
assay-based methods - carried out in different types of
cancers revealed that miR-497 (and miR-195) directly
targets the 3’-UTR region of cyclin D1 [67–69]. Al-
though, no experimental data is available to date about
the interaction of miR-497-CCND1 in colorectal cancer,
the overexpression of cyclin D1 mRNA might cause by
the underexpression of miR-497 in colorectal adenoma
and cancer by posttranscriptional silencing. Further in-
vestigations would confirmed our hypothesis.”
Conclusion
We report here a study of the levels of 1733 mature
miRNA in healthy, adenoma and colorectal cancer sam-
ples by two different methods. Besides the previously de-
scribed miRNAs in pre- and neoplastic lesions, we also
identified new, less known miRNAs (miR-4417), with al-
tered expression in different colorectal neoplastic alter-
ations. Our data also showed that tissue miRNA
expression alterations could be observed also in plasma
and may serve as valuable early diagnostic markers. Ana-
lysis of miRNA expression and predicted target mRNA
was performed from the same patient set. Negative cor-
relations were observed between miRNAs and targeted
mRNAs, which could be explored further in functional
analysis of neoplastic development related alterations.
Fig. 8 The expression of Cyclin D1 in normal epithelium (a), adenoma (b), and CRC (c) samples. Digital microscopic image; 50x magnification;
scale bar: 50 μm. The detailed Q scores of examined sample groups are illustrated (d)
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